The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density. (Q53599930)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

phase II clinical trial

0 references

author name string

Christopher P Recknor

1

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Robert R Recker

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Charles T Benson

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Deborah A Robins

4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Alan Y Chiang

5

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Jahangir Alam

6

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Leijun Hu

7

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Toshio Matsumoto

8

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Hideaki Sowa

9

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

John H Sloan

10

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Robert J Konrad

11

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Bruce H Mitlak

12

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Adrien A Sipos

13

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

publication date

11 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

30

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

9

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

1717-1725

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Public health impact of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Clinician's Guide to Prevention and Treatment of Osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

The global burden attributable to low bone mineral density.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Osteoporosis and fragility fractures: Vertebral fractures.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

The impact of nonhip nonvertebral fractures in elderly women and men.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Bone biology and anabolic therapies for bone: current status and future prospects

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Bone's mechanostat: A 2003 update

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Recent progress in osteocyte research

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Identifiers

10.1002/JBMR.2489

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25707611

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53599930&oldid=879236640"